$239 Million is the total value of PURA VIDA INVESTMENTS, LLC's 69 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OSIS | New | OSI SYSTEMS INCcall | $12,973,000 | – | 201,500 | +100.0% | 5.43% | – |
| LIVN | New | LIVANOVA PLCcall | $10,230,000 | – | 128,000 | +100.0% | 4.28% | – |
| BSX | New | BOSTON SCIENTIFIC CORPput | $5,702,000 | – | 230,000 | +100.0% | 2.39% | – |
| MZOR | New | MAZOR ROBOTICS LTDput | $4,763,000 | – | 92,300 | +100.0% | 1.99% | – |
| VNDA | New | VANDA PHARMACEUTICALS INCput | $4,560,000 | – | 300,000 | +100.0% | 1.91% | – |
| HCA | New | HCA HEALTHCARE INC | $3,953,000 | – | 45,000 | +100.0% | 1.65% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $3,897,000 | – | 43,700 | +100.0% | 1.63% | – |
| HOLX | New | HOLOGIC INC | $3,848,000 | – | 90,000 | +100.0% | 1.61% | – |
| DXCM | New | DEXCOM INCput | $3,265,000 | – | 56,900 | +100.0% | 1.37% | – |
| CVS | New | CVS HEALTH CORPcall | $3,263,000 | – | 45,000 | +100.0% | 1.36% | – |
| GMED | New | GLOBUS MED INCcall | $3,230,000 | – | 78,600 | +100.0% | 1.35% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $3,093,000 | – | 20,909 | +100.0% | 1.29% | – |
| BMY | New | BRISTOL-MYERS SQUIBB COput | $3,064,000 | – | 50,000 | +100.0% | 1.28% | – |
| MDT | New | MEDTRONIC PLC | $3,028,000 | – | 37,500 | +100.0% | 1.27% | – |
| VAR | New | VARIAN MED SYS INCput | $2,779,000 | – | 25,000 | +100.0% | 1.16% | – |
| PODD | New | INSULET CORP | $2,760,000 | – | 40,000 | +100.0% | 1.16% | – |
| MEDP | New | MEDPACE HLDGS INC | $2,538,000 | – | 70,000 | +100.0% | 1.06% | – |
| EXEL | New | EXELIXIS INC | $2,432,000 | – | 80,000 | +100.0% | 1.02% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $2,346,000 | – | 604,563 | +100.0% | 0.98% | – |
| OTIC | New | OTONOMY INC | $2,246,000 | – | 404,742 | +100.0% | 0.94% | – |
| HCA | New | HCA HEALTHCARE INCcall | $2,196,000 | – | 25,000 | +100.0% | 0.92% | – |
| INCY | New | INCYTE CORPcall | $1,894,000 | – | 20,000 | +100.0% | 0.79% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $1,880,000 | – | 5,000 | +100.0% | 0.79% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $1,870,000 | – | 275,000 | +100.0% | 0.78% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $1,762,000 | – | 433,900 | +100.0% | 0.74% | – |
| ARGX | New | ARGENX SEsponsored adr | $1,288,000 | – | 20,400 | +100.0% | 0.54% | – |
| ACER | New | ACER THERAPEUTICS INC | $1,256,000 | – | 90,660 | +100.0% | 0.53% | – |
| TSRO | New | TESARO INC | $1,243,000 | – | 15,000 | +100.0% | 0.52% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,138,000 | – | 42,186 | +100.0% | 0.48% | – |
| QTRX | New | QUANTERIX CORP | $1,058,000 | – | 49,300 | +100.0% | 0.44% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $989,000 | – | 10,000 | +100.0% | 0.41% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $818,000 | – | 60,000 | +100.0% | 0.34% | – |
| KURA | New | KURA ONCOLOGY INC | $765,000 | – | 50,000 | +100.0% | 0.32% | – |
| ACOR | New | ACORDA THERAPEUTICS INC | $751,000 | – | 35,000 | +100.0% | 0.31% | – |
| ABLX | New | ABLYNX NVsponsored adr | $735,000 | – | 29,399 | +100.0% | 0.31% | – |
| KDMN | New | KADMON HLDGS INC | $724,000 | – | 200,000 | +100.0% | 0.30% | – |
| CHRS | New | COHERUS BIOSCIENCES INCcall | $440,000 | – | 50,000 | +100.0% | 0.18% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $220,000 | – | 25,000 | +100.0% | 0.09% | – |
| AGEN | New | AGENUS INCcall | $214,000 | – | 65,700 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-02-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICU MED INC | 27 | Q2 2024 | 4.2% |
| NANOSTRING TECHNOLOGIES INC | 26 | Q2 2023 | 3.3% |
| LIVANOVA PLC | 26 | Q2 2024 | 3.8% |
| VIEWRAY INC | 25 | Q2 2023 | 3.2% |
| ESTABLISHMENT LABS HLDGS INC | 24 | Q2 2024 | 6.6% |
| INSPIRE MED SYS INC | 24 | Q1 2024 | 3.7% |
| ALEXION PHARMACEUTICALS INC | 23 | Q1 2021 | 4.3% |
| DEXCOM INC | 23 | Q1 2024 | 1.7% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2022 | 4.8% |
| INVACARE CORP | 22 | Q3 2021 | 2.8% |
View PURA VIDA INVESTMENTS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Apyx Medical Corp | February 14, 2024 | 80,000 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2024 | 1,613,844 | 3.1% |
| NanoString Technologies IncSold out | February 14, 2024 | 0 | 0.0% |
| Oncocyte Corp | February 14, 2024 | 708,172 | 8.4% |
| Quanterix Corp | February 14, 2024 | 1,935,441 | 5.2% |
| Sonendo, Inc. | February 14, 2024 | 5,422,384 | 10.0% |
| ViewRay, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| CUTERA INC | December 29, 2023 | 1,270,494 | 6.4% |
| Stryve Foods Holdings, LLC | April 19, 2023 | 1,470,649 | 5.6% |
| ICAD INC | March 15, 2023 | 1,277,214 | 5.0% |
View PURA VIDA INVESTMENTS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View PURA VIDA INVESTMENTS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.